Phio Pharmaceuticals reports complete pathologic response in 2 of 3 patients in third cohort of INTASYL PH-762 trial

Phio Pharmaceuticals Corp.

2 of 3 cSCC patients in Cohort 3 achieved 100% tumor clearance; third patient had <50% clearance.
Across 10 patients in Cohorts 1-3: 4 complete responses, 1 near complete (>90%), 1 partial (>50%).
No dose-limiting toxicities or clinically relevant adverse effects reported; PH-762 well tolerated.
Fourth cohort enrolling; Phio expects to complete trial enrollment in Q3 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.